EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care

Velislava Zoteva iD, Valerie De Meulenaere, Marthe De Boeck, Christian Vanhove, Luc Leybaert, Robrecht Raedt, Leen Pieters, Anne Vral, Tom Boterberg, Karel Deblaere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0296360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Velislava Zoteva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GB) is the most common and malignant primary brain tumor in adults with a median survival of 12–15 months. The F98 Fischer rat model is one of the most frequently used animal models for GB studies. However, suboptimal inoculation leads to extra-axial and extracranial tumor formations, affecting its translational value. We aim to improve the F98 rat model by incorporating MRI-guided (hypo)fractionated radiotherapy (3 x 9 Gy) and concomitant temozolomide chemotherapy, mimicking the current standard of care. To minimize undesired tumor growth, we reduced the number of inoculated cells (starting from 20 000 to 500 F98 cells), slowed the withdrawal of the syringe post-inoculation, and irradiated the inoculation track separately. Our results reveal that reducing the number of F98 GB cells correlates with a diminished risk of extra-axial and extracranial tumor growth. However, this introduces higher variability in days until GB confirmation and uniformity in GB growth. To strike a balance, the model inoculated with 5000 F98 cells displayed the best results and was chosen as the most favorable. In conclusion, our improved model offers enhanced translational potential, paving the way for more accurate and reliable assessments of novel adjuvant therapeutic approaches for GB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsRatsAnimalsStandard of CareRats, Inbred F344Radiotherapy Dosage

Autor:innen und Institutionen

  • Department of Radiology, Ghent University, Ghent, Belgium.
  • IBiTech-Medisip-Infinity lab, Ghent University, Ghent, Belgium.
  • Physiology Group, Department of Basic and Applied Medical Sciences, Ghent University, Ghent, Belgium.
  • Department of Head and Skin, Ghent University, Ghent, Belgium.
  • Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
  • Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.

ORCID-Profile: Velislava Zoteva

Zitieren

APA

Zoteva, V., De Meulenaere, V., De Boeck, M., Vanhove, C., Leybaert, L., Raedt, R., Pieters, L., Vral, A., Boterberg, T., & Deblaere, K. (2024). An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care. PLOS ONE. https://doi.org/10.1371/journal.pone.0296360

Vancouver

Zoteva V, De Meulenaere V, De Boeck M, Vanhove C, Leybaert L, Raedt R, et al. An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care. PLOS ONE. 2024. doi:10.1371/journal.pone.0296360

BibTeX
@article{Zoteva2024,
  author = {Zoteva, Velislava and De Meulenaere, Valerie and De Boeck, Marthe and Vanhove, Christian and Leybaert, Luc and Raedt, Robrecht and Pieters, Leen and Vral, Anne and Boterberg, Tom and Deblaere, Karel},
  title = {An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0296360}
}
Kostenlos starten →